Genocure, Signed CDMO-MSA Contract with Asymchem in China for ‘Recombinant PDRN’

Espected to become a game changer in the 300 trillion regenerative medical market

2024-11-22

Genocure Co., Ltd. (CEO Oh Bo-gyeong), a company specializing in regenerative medical biomaterials, signed a CDMO-MSA contract for ‘Recombinant PDRN’ at the Asymchem headquarters in China on Friday, November 22.

Reflecting the high interest of the Chinese authorities, many government officials including Jao Jing(赵晶), the director of the Tianjin Pharmaceutical Supervision and Administration Bureau, attended the event on this day.

Genocure stated, “Based on our own technology that can extract and produce PDRN in high purity, we have successfully developed ‘Recombinant PDRN’, a next-generation PDRN production technology. And we also obtained the results that are 100% identical to salmon DNA, the raw material for existing PDRN, in the Blast of the NCBI of United States.” It is explained that the CDMO-MSA contract for technical advancement, GMP process development, and mass production of ‘Recombinant PDRN’ was signed with Asymchem based on this achievement.

Regarding this significance of this contract, a company official said, “We will be entering the global regenerative medical market of 300 trillion won dominated by hyaluronic acid through mass production of ‘Recombinant PDRN’, a groundbreaking technology that can overcome the shortage of PDRN due to biological limitations that have been pointed out so far.”

Asymchem, founded in 1997, has strengthened its global status as a CDMO for the COVID-19 vaccine for Pfizer, recording annual sales of KRW 3 trillion. As more than 70% of its sales come from this global pharmaceutical company, it’s a comprehensive solution provider in the CDMO field that has become a key partner in the bio and pharmaceutical industries by building trust through advanced technology and strict quality control.

Regarding this contract, Oh Bo-gyeong, CEO of Genocure, stated, “The CDMO-MSA contract with Asymchem, a global CDMO company, means that Genocure’s technology has been recognized,” and she added, “Starting with the entry of Chinese, Korean, American, European markets in 2025, we will promote Genocure’s PDRN in the global regenerative medical market worth 300 trillion won and expand our pipeline by developing a ‘Recombinant PDRN’ application with Asymchem.

NextDaily

Kim Su Mi (sumi@nextdaily.co.kr)